Alzheimer's disease and nerve growth factor gene therapy.
10.11817/j.issn.1672-7347.2019.180551
- Author:
Zhonghua HUANG
1
;
Jian LI
2
;
Jun ZHOU
3
;
Jie ZHANG
1
Author Information
1. Department of Neurology, Second Xiangya Hospital, Central South University, Changsha 410011, China.
2. Department of Laboratory Medicine, Xiangya School of Medicine, Central South University, Changsha 410013, China.
3. Medical Science Research Center, Xiangya Hospital, Central South University, Changsha 410008, China.
- Publication Type:Journal Article
- MeSH:
Alzheimer Disease;
therapy;
Dependovirus;
Gene Transfer Techniques;
Genetic Therapy;
Genetic Vectors;
Humans
- From:
Journal of Central South University(Medical Sciences)
2019;44(12):1413-1418
- CountryChina
- Language:Chinese
-
Abstract:
Gene therapy plays an important role in Alzheimer's disease (AD). In recent years, the research on gene delivery vector has gradually transferred from adenovirus vector, adeno-associated virus vector and lentivirus vector to liposomes and nanomaterial carrier systems. Graphene, the newest member of nanomaterial carrier system, has attracted extensive attention for its well permeability and biocompatibility. The methods of gene therapy can be divided into direct and indirect method. The stem cell therapy, which is the most-well studied one, belongs to the indirect method. In the gene therapy of AD, the selection of appropriate carrier and method will determine the therapeutic effect.
